ArticleBMC neurology2025
Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDouble seronegative neuromyelitis optica spectrum disorder (DN-NMOSD) is a rare autoimmune disease of the central nervous system, typically involving the optic nerve and spinal cord, characterized by negativity for anti-AQP4 and anti-MOG antibodies. OBJECTIVES AND
methodsA 35-year-old man with optic neuritis and recurrent myelitis, negative for AQP4 and MOG antibodies, was diagnosed with double seronegative NMOSD (DN-NMOSD). Initial treatment with Rituximab led to temporary stability, but relapses in 2021 and 2022 prompted a switch to Satralizumab (anti-IL-6R), achieving two years of clinical and radiological stability. DISCUSSIONS AND
conclusionsThis case underscores the therapeutic potential of anti-IL-6 drugs for DN-NMOSD, especially when anti-CD20 therapies fail. It highlights the heterogeneity of DN-NMOSD and the need for novel biomarkers, such as GFAP, tau, and IL-6, to better understand disease mechanisms and guide targeted treatments. A structured therapeutic approach, starting with anti-CD20 drugs and progressing to anti-IL-6 agents if ineffective, may optimize outcomes in this poorly understood condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.